CN-121975704-A - Lactobacillus paracasei MLL28 and application thereof in antidepressant and anti-inflammatory

Abstract

The invention discloses a cheese bacillus paracasei MLL28 and application thereof in anti-depression and anti-inflammatory, belonging to the technical field of biomedicine. The strain is preserved in China general microbiological culture Collection center (CGMCC), the preservation address is CGMCC, the China national academy of sciences of China, first, second, third, and fourth, the Korean area North Star of Beijing, the preservation number is CGMCC No.37583, the preservation date is 2026, 1 month and 30 days, and the taxonomy is named as Lactobacillus paracasei Lacticaseibacillus paracasei. The strain has good tolerance to gastrointestinal tract environment, can obviously improve depression-like behaviors, regulate the levels of neurotrophic factors, neurotransmitters and inflammation-related factors, has good anti-depression and anti-inflammatory effects, and can provide a new technical approach for mood regulation, improvement of depression state and anti-inflammation.

Inventors

• ZHOU LI
• MENG LINLIN
• SUN YUTING
• MA WENJIAN
• Gou Yongming
• SONG YAJIAN
• LIU ZHONGXUE
• Kang Shujin
• XU XUETIAN

Assignees

• 天津科技大学

Dates

Publication Date

20260505

Application Date

20260408

Claims (6)

1. 1. The strain of the cheese-forming bacterium MLL28 is preserved in China general microbiological culture Collection center, which is called CGMCC for short, with a preservation address of China academy of sciences of China, west-Lou one No. three of the university of China, which is the Korean area North Star, beijing, with a preservation number of CGMCC No. 37583, a preservation date of 2026, 1 month and 30 days, and a taxonomy of the strain of the cheese-forming bacterium is named as cheese-forming bacterium Lacticaseibacillus paracasei.
2. 2. A probiotic preparation comprising the lactobacillus paracasei MLL28 of claim 1.
3. 3. Use of the lactobacillus paracasei MLL28 of claim 1 in the manufacture of an antidepressant.
4. 4. Use according to claim 3, characterized in that the effective dose of lactobacillus paracasei MLL28 is 1 x 10 9 CFU/kg.
5. 5. Use of the lactobacillus paracasei MLL28 of claim 1 in the preparation of an anti-inflammatory medicament.
6. 6. The use according to claim 5, characterized in that the effective dose of the lactobacillus paracasei MLL28 is 1 x 10 9 CFU/kg.

Description

Lactobacillus paracasei MLL28 and application thereof in antidepressant and anti-inflammatory Technical Field The invention relates to the technical field of biomedicine, in particular to a lactobacillus paracasei MLL28 and application thereof in anti-depression and anti-inflammatory. Background Depression is a common mental disorder that places a tremendous psychological and physiological burden on millions of people worldwide. Current drug therapies rely mainly on antidepressant drugs, but have side effects, leading to unstable therapeutic effects. Probiotics have demonstrated potential in regulating intestinal microbiota and improving mental health. More and more studies have shown that probiotics can affect the occurrence and development of depression by interacting with the host's immune, nervous and endocrine systems. Probiotics are a class of beneficial microorganisms that are of interest because of their role in maintaining ecological balance in the human intestinal tract. More intensive studies have revealed that there is a close link between the gut and the brain, the so-called "gut-brain-axis", which discovery provides a theoretical basis for probiotics to actively intervene in depression and anxiety by modulating the gut microflora. The intake of probiotics is not only helpful for maintaining the balance of intestinal flora and reducing the growth of harmful bacteria, but also can promote the propagation of beneficial bacteria. These probiotics are capable of producing metabolites in the gut that are beneficial to the brain, such as short chain fatty acids and neurotransmission substances, affecting emotional and psychological states through the "gut-brain-axis". Notably, the positive impact of probiotics on mental health has also been associated with their ability to regulate brain-derived neurotrophic factor (BDNF) levels. BDNF is a protein that plays a key role in the brain, is critical for neuronal survival, growth and differentiation, and changes in its levels are closely related to the amelioration of depression and anxiety symptoms. Meanwhile, probiotics are helpful for reducing the inflammation level related to psychological stress by reducing the production of inflammatory factors, and further promote psychological health. In summary, the potential role of probiotics in improving depression and anxiety not only opens up the possibility of using them as novel therapeutic means, but also provides new scientific basis for mental health intervention. However, existing probiotic products that are effective in improving anxiety and depression are relatively few. Therefore, how to develop a microbial preparation that can effectively improve anxiety and depression is a problem that has been urgently needed to be solved by those skilled in the art. Disclosure of Invention In view of the above, the present invention aims to provide a strain of lactobacillus paracasei MLL28 and its application in anti-depression and anti-inflammatory, so as to solve the deficiencies in the prior art. In order to achieve the above purpose, the present invention adopts the following technical scheme: the strain of the cheese-forming bacterium MLL28 is preserved in China general microbiological culture Collection center (CHINA GENERAL Microbiological Culture Collection Center), which is called CGMCC for short, the preservation address is CGMCC No. 37583, the preservation date is 2026, 1 month and 30 days, and the taxonomy is named as the cheese-forming bacterium Lacticaseibacillus paracasei. The Lactobacillus paracasei MLL28 of the present invention is capable of surviving simulated gastric acid conditions at a pH of 2.0-3.0 and is tolerant to bile salt environments of 0.1% -0.5%. The Lactobacillus paracasei MLL28 has good intestinal epithelial cell adhesion capability. The cheese-making bacillus paracasei MLL28 can regulate the intracellular active oxygen level and up-regulate the expression of the neurotrophic related factors BDNF and CREB in an in vitro PC12 cell model. The lactobacillus paracasei MLL28 of the present invention plays a role in improving depression-like behavior by regulating the levels of neurotrophic related factors and neurotransmitters, and regulating intestinal inflammation. The lactobacillus paracasei MLL28 of the present invention exerts an antidepressant effect by the following mechanism: 1. The balance of neurotransmitters is regulated by the "gut-brain-axis", in particular increasing GABA (gamma-aminobutyric acid) levels, thereby improving mood. 2. Inhibit chronic low-grade inflammatory reaction in intestinal tract and body, reduce inflammation of nervous system, and protect nerve function. A probiotic preparation contains the above Lactobacillus paracasei MLL28. The invention also claims the application of the Lactobacillus paracasei MLL28 in preparing antidepressant drugs. Further, the effective dose of the above-mentioned Lactobacillus paracasei MLL28 was 1X 10 9 CFU/kg. The invention